Why is Lincoln Pharma. falling/rising?

As of 26-Aug, Lincoln Pharmaceuticals Ltd is experiencing a decline in its stock price, currently at 542.40, which reflects a decrease of 0.55 or 0.1%. The stock has been underperforming recently, having fallen consecutively for the last two days with a total return of -1.99%. It is trading below its 5-day, 20-day, 50-day, 100-day, and 200-day moving averages, indicating a bearish trend. Additionally, the stock's delivery volume has decreased by 1.62% against the 5-day average, suggesting a drop in investor participation. Over the past year, the stock has generated a return of -23.79%, significantly underperforming the broader market, which has seen a decline of only 1.12%.
In the broader market context, Lincoln Pharmaceuticals has struggled compared to the benchmark, with a 1-year return that is substantially worse than the BSE500's negative return of -3.87%. The company's financials indicate poor long-term growth, with net sales and operating profit growing at annual rates of only 9.87% and 7.84%, respectively, over the last five years. Furthermore, the company's low debt-to-equity ratio and attractive valuation metrics are overshadowed by its declining profits, which have fallen by 11.8%. The lack of investment from domestic mutual funds, which hold 0% of the company, may reflect a lack of confidence in its current valuation or business prospects, contributing to the stock's downward movement.